Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810083 | 0.90 | PPARG (0.54) | PPARGPPARATP53FOLH1 | |
| SCHEMBL2807202 | 0.87 | PTGER4 (0.44) | PPARGPTGER4TP53CNR2FOLH1 | |
| SCHEMBL14270619 | 0.85 | PPARG (0.50) | PPARGPPARATP53FOLH1 | |
| SCHEMBL2813912 | 0.85 | SERPINE1 (0.42) | PPARGPTGER4TP53CNR2FOLH1 | |
| SCHEMBL2811167 | 0.83 | PTGER4 (0.42) | PPARGPTGER4TP53CNR2FOLH1 | |
| SCHEMBL2810329 | 0.83 | SERPINE1 (0.42) | PPARGPTGER4KMT2A | |
| SCHEMBL2807458 | 0.81 | PPARG (0.45) | PPARGPTGER4FOLH1MEN1KMT2A | |
| SCHEMBL13168304 | 0.78 | PPARG (0.41) | PPARGPTGER4CNR2FOLH1KMT2A | |
| Gsk-376501 SCHEMBL2813131 | 0.78 | SERPINE1 (0.54) | PPARGFOLH1 | |
| Gsk-376501 SCHEMBL29810243 | 0.78 | SERPINE1 (0.54) | PPARGFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2081894-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SmithKline Beecham Corporation (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PTGER4 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.